KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Equity Ratio (2019 - 2025)

Historic Equity Ratio for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to 0.5.

  • Royalty Pharma's Equity Ratio fell 1275.97% to 0.5 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.5, marking a year-over-year decrease of 1275.97%. This contributed to the annual value of 0.5 for FY2025, which is 1275.97% down from last year.
  • According to the latest figures from Q4 2025, Royalty Pharma's Equity Ratio is 0.5, which was down 1275.97% from 0.5 recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Equity Ratio registered a high of 0.63 during Q2 2021, and its lowest value of 0.5 during Q4 2025.
  • Moreover, its 5-year median value for Equity Ratio was 0.58 (2022), whereas its average is 0.57.
  • Per our database at Business Quant, Royalty Pharma's Equity Ratio surged by 865.7% in 2023 and then plummeted by 1275.97% in 2025.
  • Royalty Pharma's Equity Ratio (Quarter) stood at 0.59 in 2021, then dropped by 3.17% to 0.57 in 2022, then grew by 8.66% to 0.62 in 2023, then decreased by 7.8% to 0.57 in 2024, then dropped by 12.76% to 0.5 in 2025.
  • Its Equity Ratio stands at 0.5 for Q4 2025, versus 0.5 for Q3 2025 and 0.52 for Q2 2025.